NeonMind Announces Launch of Functional Mushroom Coffees as Dietary
Supplements in the US
Vancouver,
B.C., Canada -- June 29, 2021 -- InvestorsHub NewsWire -- NeonMind
Biosciences Inc. (CSE:
NEON) (OTC:
NMDBF) (FRA:
6UF)
("NeonMind''
or the "Company"),
a psychedelic drug development company, is pleased to announce that
it has launched its NeonMind branded functional mushroom coffee
products as dietary supplements in the United States. The
initial launch includes two ground coffee SKUs that are now
available for delivery anywhere within the US. Two instant
coffee SKUs are anticipated to be added within a month.
The new website
for US sales is live at intl.neonmind.com and is supported by
Shopify. Products can be purchased individually and can be ordered
as a subscription to receive a 10% discount The website was
built to be mobile friendly and focus on a customer-first strategy.
Consumers can sign up to NeonMind's newsletter to receive the
latest news, product releases and recipe information.
Each of the
functional mushroom blends and botanicals selected in NeonMind
coffees include adaptogens, which means that they work with one's
body to help manage physical, mental and emotional
stressors. Functional mushroom
specifically refers to mushroom varieties that have a health
benefit beyond providing nutrition. Functional mushrooms found in
NeonMind coffees, such as cordyceps, lion's mane, reishi, and
turkey tail; offer long-term physical, neurological and
immunological benefits.
The initial
product launch will feature two varieties of ground coffee. The
Protect Blend is a Peruvian Medium Roast French Vanilla Coffee,
Turkey Tail, Cordyceps, Moringa extract, and Amla extract. These
ingredients have the proven benefit of stress relief, immune
support, and cognitive support. The Focus Blend is a Peruvian Dark
Roast Coffee with Lion's Mane extract, Reishi extract, Gotu Kola
extract, and Brahmi extract. These ingredients are a healthy source
of fungal polysaccharides with immuno-modulating properties that
help improve memory and cognitive function, increase alertness,
support the immune system and fight mental and physical stress. The
Company will soon launch its two instant coffee blends in the US as
dietary supplements.
The NeonMind coffee dietary supplements follow all FDA regulations
that focus on Comprehensive GMP (Good Manufacturing Practices) to
ensure the identity, purity, quality, strength and composition of
dietary supplements. NeonMind only uses certified organic mushroom
extracts which go through the decoction process (traditional water
boiling) to maximize the bioavailability of the
product.
NeonMindfollows strict US
pharmacopeia guidelines for lead and other chemicals required by
Proposition 65 for safe and daily intake. All final production
batches are sent to a third party lab for stringent microbial
testing in order for the copacker to release the product
certificate of analysis which signifies that the product is safe
for the consumer market.
The global
functional mushroom market was valued at USD $25.4 billion in 2020, and it
is estimated to register a compound annual growth rate of 8.44%
during the forecast period 2021-2026, according to a report by
Mordor Intelligence.
About NeonMind Biosciences Inc.
NeonMind is engaged in
preclinical research to develop potential clinical treatments and
wellness products to address obesity and weight management
conditions and to promote health and wellness. The Company operates
three divisions: (i) a pharmaceutical division engaged in drug
development of psychedelic compounds with two lead psilocybin-based
drug candidates targeting obesity; (ii) a medical services division
focused on launching specialty mental health clinics that integrate
psychedelic therapeutics into traditional psychotherapy settings;
and (iii) a consumer products division that currently sells
mushroom-infused products to promote health and
wellness.
In its pharmaceutical
division, NeonMind has two distinct psilocybin drug development
programs targeting obesity. NeonMind's first drug candidate employs
psilocybin as an agonist to the serotonin receptor 5- HT2A, which
is involved in the hallucinogenic effect of psychedelics. The
Company's second drug candidate employs low-dose psilocybin as an
agonist to the 5-HT2C receptor, which controls appetite.
NeonMind established a
medical services division with the goal of launching
NeonMind-branded specialty mental health clinics in Canada that
incorporate evidence-backed innovative treatments to address a
variety of mental health needs.
NeonMind's consumer division
currently sells NeonMind branded coffee products in Canada through
NeonMind's direct to consumer e-commerce platform in Canada and the
US.
For more information on
NeonMind, go to www.NeonMindBiosciences.com.
Rob
Tessarolo, President & Chief Executive Officer, NeonMind
Biosciences Inc.
rob@neonmind.com
Tel: 416-750-3101
Investor
Relations:
Edge
Communications
invest@neonmind.com
Tel:
1-866-318-6874
KCSA
Strategic Communications
Scott
Eckstein/Tim Regan
neonmind@kcsa.com
Tel: 212-896-1210
Media
Inquiries:
KCSA Strategic Communications
Annie
Graf
neonmind@kcsa.com
Tel: 786-390-2644
The
Canadian Securities Exchange has not reviewed, approved nor
disapproved the contents of this news release.
Cautionary Statement Regarding Forward-Looking Statements
Certain statements contained in this press release constitute
forward-looking information. These statements relate to future
events or NeonMind's future performance. The use of any of the
words "could", "expect", "believe", "will", "projected","estimated"
and similar expressions and statements relating to matters that are
not historical facts are intended to identify forward-looking
information and are based on NeonMind's current belief or
assumptions as to the outcome and timing of such future events.
Actual future results may differ materially. In particular,
NeonMind's drug development plans, its ability to retain key
personnel, and its expectation as to the development of its
intellectual property and other steps in its preclinical and
clinical drug development constitute forward-looking information.
Actual results and developments may differ materially from those
contemplated by forward-looking information. Readers are cautioned
not to place undue reliance on forward-looking information. The
statements made in this press release are made as of the date
hereof. NeonMind disclaims any intention or obligation to publicly
update or revise any forward-looking information, whether as a
result of new information, future events or otherwise, except as
may be expressly required by applicable securities laws.